NVCR · NovoCure Ltd
United States · RS rating 38 · As of 2026-11-03
| Price | 13.43 USD |
|---|---|
| 1-day change | +1.7% |
| RS rating (overall / 1M / 3M / 12M) | 38 / 32 / 36 / 56 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 28 / 28 / 43 |
| Industry group (rank) | Medical-Products (106) |
| EPS growth Q/Q | +33.3% |
| Sales growth Q/Q | +4.3% |
| Distance from 52-week high | +32.8% |
| Market cap (USD) | $1.5B |